Valerio Benedetti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Valerio Benedetti has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Sessa
Neuroepigenetics Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy
1 shared publication - Edoardo Bellini
IFOM ETS, the AIRC Institute of Molecular Oncology, Milan, Italy
1 shared publication - Federica Banfi
Stem Cell and Neurogenesis Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute
1 shared publication - Gabriele Ordazzo
Division of Neuroscience, San Raffaele Scientific Institute
1 shared publication - Giuseppina Mastrototaro
Stem Cell and Neurogenesis Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
1 shared publication - Laura Argelich
Stem Cell and Neurogenesis Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
1 shared publication
Latest Publications
- Open Access
- 5 August 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (31) , eabn3986
A SOX2-engineered epigenetic silencer factor represses the glioblastoma genetic program and restrains tumor development
Current therapies remain unsatisfactory in preventing the recurrence of glioblastoma multiforme (GBM), which leads to poor patient survival. By rational engineering of the transcription factor SOX2, a key promoter of GBM malignancy, together with the Kruppel-associated box and DNA methyltransferase3A/L catalytic domains, we generated a synthetic repressor named SOX2 epigenetic silencer (SES), which induces the transcriptional silencing of its original targets. By doing so, SES kills both glioma cell lines and patient-derived cancer stem cells in vitro and in vivo. SES expression, through local viral delivery in mouse xenografts, induces strong regression of human tumors and survival rescue. Conversely, SES is not harmful to neurons and glia, also thanks to a minimal promoter that restricts its expression in mitotically active cells, rarely present in the brain parenchyma. Collectively, SES produces a significant silencing of a large fraction of the SOX2 transcriptional network, achieving high levels of efficacy in repressing aggressive brain tumors.
- 5 August 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (31) , eabn3986
Open AccessA SOX2-engineered epigenetic silencer factor represses the glioblastoma genetic program and restrains tumor development
Current therapies remain unsatisfactory in preventing the recurrence of glioblastoma multiforme (GBM), which leads to poor patient survival. By rational engineering of the transcription factor SOX2, a key promoter of GBM malignancy, together with the Kruppel-associated box and DNA methyltransferase3A/L catalytic domains, we generated a synthetic repressor named SOX2 epigenetic silencer (SES), which induces the transcriptional silencing of its original targets. By doing so, SES kills both glioma cell lines and patient-derived cancer stem cells in vitro and in vivo. SES expression, through local viral delivery in mouse xenografts, induces strong regression of human tumors and survival rescue. Conversely, SES is not harmful to neurons and glia, also thanks to a minimal promoter that restricts its expression in mitotically active cells, rarely present in the brain parenchyma. Collectively, SES produces a significant silencing of a large fraction of the SOX2 transcriptional network, achieving high levels of efficacy in repressing aggressive brain tumors.